Longview Partners Guernsey LTD Sells 295,800 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Longview Partners Guernsey LTD lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 11.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,227,405 shares of the medical research company’s stock after selling 295,800 shares during the quarter. IQVIA accounts for 3.5% of Longview Partners Guernsey LTD’s holdings, making the stock its 20th biggest position. Longview Partners Guernsey LTD owned approximately 1.22% of IQVIA worth $470,963,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Rise Advisors LLC bought a new position in shares of IQVIA in the first quarter worth $31,000. Versant Capital Management Inc increased its position in shares of IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after buying an additional 110 shares during the period. Riverview Trust Co acquired a new stake in shares of IQVIA during the first quarter worth $32,000. Opal Wealth Advisors LLC acquired a new stake in IQVIA in the second quarter worth $27,000. Finally, International Assets Investment Management LLC acquired a new stake in IQVIA in the second quarter worth $32,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 1.0 %

IQVIA stock opened at $242.24 on Friday. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The stock’s 50 day simple moving average is $240.60 and its two-hundred day simple moving average is $234.19. The firm has a market cap of $44.16 billion, a PE ratio of 33.09, a P/E/G ratio of 2.25 and a beta of 1.49.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. The company had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.22 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Morgan Stanley raised their price target on shares of IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, July 23rd. JPMorgan Chase & Co. boosted their price target on shares of IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research note on Monday, August 5th. Royal Bank of Canada began coverage on shares of IQVIA in a report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price objective for the company. Argus upgraded shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Finally, Jefferies Financial Group lowered shares of IQVIA from a “buy” rating to a “hold” rating and lowered their price target for the company from $266.00 to $242.00 in a report on Wednesday, July 24th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $267.00.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.